cisplatin,gemcitabine,durvalumab
astrazeneca
['confirm,(-confirma),(-confirme)', 'topaz-1', 'cisplatin', 'durva', 'gemcitabine']
#esmo22:updated os data from topaz-1 confirm the clinically meaningful benefit of adding durvalumab to cisplatin/gemcitabine in advanced/metastatic biliary tract cance 
The European Society for Medical Oncology (ESMO) is the leading organisation for cancer education and information, supporting the oncology community’s work.